Rosemarie Lajara

Summary

Publications

  1. ncbi request reprint Efficacy and Safety of Linagliptin in Subjects With Long-standing Type 2 Diabetes Mellitus (>10 Years): Evidence From Pooled Data of Randomized, Double-blind, Placebo-controlled, Phase III Trials
    Rosemarie Lajara
    Diabetes America, Plano, Texas Electronic address
    Clin Ther 36:1595-605. 2014
  2. ncbi request reprint The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus
    Rosemarie Lajara
    Diabetes America, Health Center At Plano, Plano, TX, USA
    Expert Opin Pharmacother 15:2565-85. 2014
  3. ncbi request reprint Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes
    Rosemarie Lajara
    Diabetes America, Health Center At Plano, 1708 Coit Road, Suite 100, Plano, TX 75075, USA
    Expert Opin Pharmacother 13:2663-71. 2012
  4. ncbi request reprint Healthcare professional and patient perceptions of a new prefilled insulin pen versus vial and syringe
    Rosemarie Lajara
    Diabetes Centers of America, Health Center At Plano, 1708 Coit Road Suite 100, Plano, TX 75075, USA
    Expert Opin Drug Deliv 9:1181-96. 2012

Detail Information

Publications4

  1. ncbi request reprint Efficacy and Safety of Linagliptin in Subjects With Long-standing Type 2 Diabetes Mellitus (>10 Years): Evidence From Pooled Data of Randomized, Double-blind, Placebo-controlled, Phase III Trials
    Rosemarie Lajara
    Diabetes America, Plano, Texas Electronic address
    Clin Ther 36:1595-605. 2014
    ..This study aimed to assess the efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in an understudied population of patients with long-standing T2DM...
  2. ncbi request reprint The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus
    Rosemarie Lajara
    Diabetes America, Health Center At Plano, Plano, TX, USA
    Expert Opin Pharmacother 15:2565-85. 2014
    ..As part of the extensive clinical development programs for modern T2DM therapies, SGLT2 inhibitors have been studied in combination with the most commonly used classes of glucose-lowering medications...
  3. ncbi request reprint Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes
    Rosemarie Lajara
    Diabetes America, Health Center At Plano, 1708 Coit Road, Suite 100, Plano, TX 75075, USA
    Expert Opin Pharmacother 13:2663-71. 2012
    ....
  4. ncbi request reprint Healthcare professional and patient perceptions of a new prefilled insulin pen versus vial and syringe
    Rosemarie Lajara
    Diabetes Centers of America, Health Center At Plano, 1708 Coit Road Suite 100, Plano, TX 75075, USA
    Expert Opin Drug Deliv 9:1181-96. 2012
    ..Usability of a new prefilled insulin pen, FlexTouch® (FT; Novo Nordisk A/S, Bagsvaerd, Denmark), with no push-button extension and low injection force, was compared with vial and syringe (V&S)...